Safety and Efficacy of AS101 1% Oral Solution in Patients With Neovascular Age-Related Macular Degeneration (AMD)
Status:
Completed
Trial end date:
2020-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of AS101 1% oral solution as
compared to placebo in patients with neovascular Age-Related Macular Degeneration (AMD).
AMD Patients who underwent 3 consecutive intravitreal anti VEGF injections and have sub
retinal or intraretinal fluid at day 1 of study will be treated orally by AS101 1% solution
or placebo once daily for 24 weeks and will be tested for sub retinal or intraretinal fluid
every 4 weeks by OCT examination. In case of fluid in macula anti intravitreal anti VEGF
injections will be given the same day as needed (PRN). Safety evaluation will be assessed by
adverse events related to treatment of 1% AS101 oral solution or placebo. Efficacy will be
evaluated in terms of duration of fluid free macula in the AS101 treated group as as compared
to placebo treated group;